Sachetta LLC Acquires 13,544 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS)

Sachetta LLC lifted its holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 12.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 118,354 shares of the company’s stock after acquiring an additional 13,544 shares during the period. Sachetta LLC’s holdings in Sensus Healthcare were worth $631,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Chapin Davis Inc. bought a new position in Sensus Healthcare during the 2nd quarter worth $53,000. Hillsdale Investment Management Inc. bought a new stake in shares of Sensus Healthcare during the 1st quarter valued at $155,000. Creekmur Asset Management LLC acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth $83,000. Finally, Acadian Asset Management LLC increased its position in shares of Sensus Healthcare by 578.6% in the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after purchasing an additional 38,474 shares during the period. 25.30% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on SRTS shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sensus Healthcare in a research report on Monday, August 12th. Roth Capital raised shares of Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $5.80 on Tuesday. Sensus Healthcare, Inc. has a 52-week low of $1.79 and a 52-week high of $7.18. The firm has a market cap of $95.06 million, a price-to-earnings ratio of 20.00 and a beta of 1.05. The business’s fifty day moving average is $6.15 and its 200-day moving average is $5.05.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. The firm had revenue of $9.24 million for the quarter, compared to analysts’ expectations of $7.00 million. Sensus Healthcare had a return on equity of 13.46% and a net margin of 18.27%. During the same quarter in the previous year, the business posted ($0.02) earnings per share. As a group, research analysts forecast that Sensus Healthcare, Inc. will post 0.36 EPS for the current fiscal year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.